Trial
NCT03835728
Efficacy of Ocrelizumab in Autoimmune Encephalitis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Texas Southwestern Medical Center
Collaborators
Genentech, Inc.
Condition
Autoimmune Encephalitis
Intervention
Ocrelizumab
Why stopped
Failed to meet target enrollment and study was discontinued
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-19